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The cytokine transforming growth factor-β (TGF-β) plays a pivotal role in a diverse range of
cellular responses, including cell proliferation, apoptosis, differentiation, migration, adhe-
sion, angiogenesis, stimulation of extracellularmatrix (ECM) synthesis, and downregulation
of ECM degradation.TGF-β and its receptors are ubiquitously expressed by most cell types
and tissues in vivo. In intact adult tissues and organs,TGF-β is secreted in a biologically inac-
tive (latent) form associated in a non-covalent complex with the ECM. In response to injury,
local latentTGF-β complexes are converted into activeTGF-β according to a tissue- and injury
type-speciﬁc activation mechanism. Such a well and tightly orchestrated regulation inTGF-β
activity enables an immediate, highly localized response to type-speciﬁc tissue injury. In
the pathological process of liver ﬁbrosis, TGF-β plays as a master proﬁbrogenic cytokine in
promoting activation and myoﬁbroblastic differentiation of hepatic stellate cells, a central
event in liver ﬁbrogenesis. Continuous and/or persistentTGF-β signaling induces sustained
production of ECM components and of tissue inhibitor of metalloproteinase synthesis.
Therefore, the regulation of locally activated TGF-β levels is increasingly recognized as a
therapeutic target for liver ﬁbrogenesis.This review summarizes our present knowledge of
the activation mechanisms and bioavailability of latent TGF-β in biological and pathological
processes in the liver.
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INTRODUCTION
Transforming growth factor-β (TGF-β) is a member of the TGF-
β super-family, which also includes bone morphogenic pro-
teins, activins, inhibins, and other related factors (Moustakas and
Heldin, 2009). Mammals have three different forms of TGF-β
(β1, β2, and β3). The ligands initiate their cellular effects using
high-afﬁnity cell surface receptors (TGF-β type I and type II recep-
tors). The importance of each TGF-β isoforms in mammalian
biology is highlighted by their lethal phenotypes in TGF-β-null
mice. For instance, 50 percent of TGF-β1-null mouse fetuses die
around 10.5 days post coitum (dpc) due to abnormal develop-
ment of the yolk sac, characterized by defective vasculogenesis
and/or anemia during embryonic development (Dickson et al.,
1995). Even in newborn TGF-β1-null mice, severe multi-organ
autoimmunity and multi-focal inﬂammation develop after birth:
the mice die within 3weeks due to widespread inﬂammatory dis-
ease (Shull et al., 1992; Kulkarni et al., 1993). TGF-β2-null mice
die in the perinatal period due to cyanotic heart disease and pul-
monary insufﬁciency (Sanford et al., 1997). TGF-β3-null mice die
Abbreviations: α-SMA, α-smooth muscle actin; ADAMTS1, a disintegrin and
metalloproteinase with thrombospondin motifs 1; CCl4, carbon tetrachloride;
DMN, dimethylnitrosamine; ECM, extracellular matrix; HSC, hepatic stellate cell;
HUVECs, human umbilical vein endothelial cells; LAP, latency-associated pep-
tide; LTBP, latent TGF-β binding protein; MMP, matrix metalloproteinase; TGF-β,
transforming growth factor-β; TSP-1, thrombospondin-1.
of craniofacial defects, most notably cleft palate (Proetzel et al.,
1995). Thus, TGF-β signaling is an important for tissue growth
and morphogenesis with clear roles in processes such as vascu-
logenesis, angiogenesis, immune response, and development of
the palate during embryonic development, and homeostasis after
birth. Although TGF-β was initially identiﬁed as a growth fac-
tor that induced the growth of rodent ﬁbroblasts in semi-solid
agar, TGF-βs are now also known to be potent growth inhibitors
for many different cell types, including epithelial cells, endothelial
cells, hematopoietic progenitor cells, and lymphocytes (Siegel and
Massague, 2003). Albumin promoter-mediated overexpression of
TGF-β1 in transgenic mice can result in abnormal phenotypes
characterized by hepatocyte apoptosis and liver ﬁbrosis, and also
causes glomerulonephritis, renal failure, arteritis,myocarditis, and
atrophic changes in pancreas and testis (Sanderson et al., 1995).
Thus, TGF-βs play a pivotal role in a diverse range of cellular
responses, including cell proliferation, apoptosis, differentiation,
migration, adhesion, angiogenesis, and synthesis of extracellular
matrix (ECM) components (Feng and Derynck, 2005; ten Dijke
andArthur, 2007;Wakeﬁeld and Stuelten, 2007), and thereby con-
trol embryonic development and adult tissue homeostasis. Hence,
any dysregulation in the control of TGF-β signaling contributes to
the development of severe consequences like as ﬁbrosis, autoim-
mune and vascular diseases, and cancer (Sellheyer et al., 1993;
Galbreath et al., 1995; Sanderson et al., 1995; Zhou et al., 1996;
Blobe et al., 2000; Feng and Derynck, 2005; ten Dijke and Arthur,
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2007; van Bezooijen et al., 2007; Wakeﬁeld and Stuelten, 2007).
Because TGF-β and its receptors widely express in all cell types, a
tight regulation at every step of its synthesis, activation, and the
downstream signaling must be required for keeping tissue home-
ostasis in normal liver. Latency is one mechanism by which to
control the activity of a cytokine; latency prevents the cytokine
from eliciting a response until conversion to the active form and
may also allow the cytokine to circulate and reach its target cell.
TGF-β is synthesized and secreted as a latent complex and is con-
verted from the latent form into the active one to bind to its
high-afﬁnity TGF-β receptor. Recently, activation of latent TGF-β
is being increasingly recognized as a critical step in the control of
TGF-β activity (Koli et al., 2001; Annes et al., 2003; Hyytiainen
et al., 2004; Wipff and Hinz, 2008). Indeed, enhanced expression
of TGF-β mRNA and protein levels does not often correlate with
active TGF-β level (Theodorescu et al., 1991). In addition, latent
TGF-β activation can be induced independently of transcription
(Boulanger et al., 1995). The aim of this review is to summarize the
present knowledge of TGF-β activation mechanism in the liver.
SYNTHESIS (PLEASE SEE FIGURE 1)
SMALL LATENT COMPLEX
The isoforms of TGF-β1, -2, and -3 are encoded as large precursor
proteins of 390–412 amino acids in size, and each isoform is the
product of a separate gene (Derynck et al., 1985; Gentry and Nash,
1990; tenDijke et al., 1990; Schlunegger andGrutter, 1992). TGF-β
proteins undergo several processing steps intracellularly prior to
their secretion. The most important step is the proteolytic diges-
tion of precursors by the endopeptidase furin, which cleaves the
TGF-β protein between amino acids 278 and 279 (Dubois et al.,
1995; Blanchette et al., 1997). The proteolysis yields two prod-
ucts that assemble into dimers. One is latency-associated peptide
(LAP), a 65- to 75-kDa dimer from the N-terminal region. The
other is mature TGF-β, a 25-kDa dimer from the C-terminal por-
tion (Gentry and Nash, 1990; Blanchette et al., 1997; Munger et al.,
1997). A common feature of TGF-β is that its N-terminal por-
tion (LAP) remains non-covalently associated with the rest of the
portion (termed small latent complex), despite the cleavage of the
precursor (Derynck et al., 1985; Gentry and Nash, 1990; ten Dijke
et al., 1990; Schlunegger and Grutter, 1992; Dubois et al., 1995;
Blanchette et al., 1997; Munger et al., 1997). The presence of LAP
facilitates transit of TGF-β from the cell (Lopez et al., 1992). Inter-
estingly, cells transfected with mature sequences of TGF-β1 fail to
secrete proteins into medium, whereas cells transfected with LAP
and mature sequences of TGF-β1 can do this (Gray and Mason,
1990). Thus, LAP is required for the correct folding of the TGF-β
homodimer and its secretion from cells. Furthermore, LAP shields
the receptor binding epitope of mature TGF-β, indicating that
LAP makes TGF-β biologically inactive and prevents interactions
of TGF-β with receptors.
LARGE LATENT COMPLEX
Small latent complex is associated with a large protein termed
latent TGF-β binding protein (LTBP) via disulﬁde bonds. Mam-
malian cells express four different LTBP isoforms, of which three
(LTBP-1, -3, and -4) can associate with LAP. The trimolecular
complex of TGF-β, LAP, and LTBP is referred to as the large
FIGURE 1 | Illustration of the sequential steps in the synthesis ofTGF-β
latent complex and secretion. (1) TGF-β is synthesized as a precursor
protein; (2) TwoTGF-β precursor proteins dimerize through disulﬁde bridges;
(3) TGF-β-dimer precursor is cleaved by furin to yield the small latent TGF-β
complex, in which latency-associated peptide (LAP; light blue) and mature
TGF-β peptide (dark blue) are connected by non-covalent bonds; and (4) the
large latent complex is formed by covalent linking between small latent
complex and latent TGF-β binding protein (LTBP), then secreted and
incorporated into extracellular matrix.
latent complex. In most cell types, TGF-β is secreted as large
latent TGF-β complexes (Olofsson et al., 1992; Taipale et al.,
1994), although some cells (such as those of the bone cell line
UMR-106) secrete small latent complex (Dallas et al., 1994).
LTBPs contain multiple epidermal growth factor-like repeats and
four cysteine-rich domains that are also found in ﬁbrillins. Dur-
ing secretory processes, the cysteine 33 residue of TGF-β1–LAP
becomes disulﬁde-linked to the third cysteine-rich domain in
LTBP-1 (Saharinen et al., 1996). In mice with the mutation (cys-
teine 33 residue to serine) of TGF-β1–LAP, mutated TGF-β1–LAP
cannot covalently complex with any LTBP, and TGF-β1 is secreted
as small latent complex (Yoshinaga et al., 2008). Furthermore,mice
with the mutation of cysteine 33 in LAP display decreased lev-
els of active TGF-β1 compared with control mice, show a milder
multi-organ inﬂammation, and have a longer life span than TGF-
β1-nullmice (Yoshinaga et al., 2008). Large latent TGF-β1 complex
(small latent TGF-β1 with LTBP) and the free form of LTBP are
secreted rapidly from cells (Miyazono et al., 1991). In contrast,
the small latent form of TGF-β without LTBP is secreted very
slowly (Miyazono et al., 1991), and the majority of latent TGF-β
without LTBP is retained in the cis aspect of the Golgi apparatus
(Miyazono et al., 1992). Thus, LTBP associates with small latent
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TGF-β rapidly inside the cells, and this association is important
for the proper assembly and secretion of latent TGF-β complexes
(Miyazono et al., 1991).
ECM ANCHORING
After secretion, LTBP also plays a critical role in targeting small
latent TGF-β for deposition in the ECM(Taipale et al., 1994;Nunes
et al., 1997). LTBP belongs to the ﬁbrillin family of ECM pro-
teins, and LTBP shares homology with ﬁbrillins, which are major
constituents of connective tissue microﬁbrillar structure (Kanzaki
et al., 1990; Munger et al., 1997). The C-terminal region of LTBP-1
binds to the N-terminal region of ﬁbrillin-1 (Isogai et al., 2003).
In addition, LTBP-1 is covalently cross-linked to ECM proteins
such as ﬁbronectin (Dallas et al., 2005) via its N-terminal region
(Taipale et al., 1994;Nunes et al., 1997). Indeed, LTBP-1 colocalizes
with both ﬁbrillin-1 and ﬁbronectin in vitro by immunostain-
ing (Taipale et al., 1996; Dallas et al., 2005; Massam-Wu et al.,
2010), suggesting that ﬁbrillin-1and ﬁbronectin can associate with
LTBP-1. The treatment of fetal rat calvarial osteoblasts with a 70-
kDa N-terminal ﬁbronectin fragment, which inhibits ﬁbronectin
assembly, impairs incorporation of LTBP-1 into the ECM in cul-
ture (Dallas et al., 2005). In addition, although ﬁbronectin-null
embryonic ﬁbroblasts secrete a large amount of LTBP-1 into
medium, they fail to incorporate LTBP-1 into the ECM (Dal-
las et al., 2005). This covalent association between LTBP-1 and
the ECM depends on transglutaminase-mediated cross-linking,
because little LTBP-1 is recovered from matrix digests that have
been treated with transglutaminase inhibitors (Nunes et al., 1997).
Thus, the N-terminal and C-terminal binding sites of LTBP-1 are
central for anchoring latent TGF-β to ﬁbrillin-1 and ﬁbronectin
(Hyytiainen et al., 1998; Unsold et al., 2001), and this anchor-
ing inﬂuences the release of TGF-β from LAP, a process called
latent TGF-β activation (Annes et al., 2004). A number of genetic
studies suggest that the absence of or a mutation in LTBP-binding
ECMs such as ﬁbrillin-1 and ﬁbronectin results in increased TGF-
β activity and Smad signaling, whereas the absence of or mutation
in latent TGF-β activators and LTBPs results in decreased activ-
ity (Neptune et al., 2003; Koli et al., 2004; Mazzieri et al., 2005;
Yoshinaga et al., 2008; Loeys et al., 2010; Table 1). Efﬁcient latent
TGF-β activation requires appropriate localization of latent com-
plexes in the ECM (Annes et al., 2003). Following the N-terminal
domain of LTBP, there is a protease-sensitive region, called the
hinge region. Large latent TGF-β is released from the ECM by
proteolytic cleavage at this region (Taipale et al., 1994). Thus, the
small latent complex,which consists of precursors of mature TGF-
β and LAP, covalently interacts with LTBP and is secreted thereafter
as a large latent complex. The large latent complex is then asso-
ciated with the ECM such as ﬁbrillin and ﬁbronectin (Figure 2).
Extracellular TGF-β activity is regulated at the level of bioavail-
ability (release of latent TGF-β from ECM) and latency (release
of active TGF-β from the latent complex). Such a well and tightly
orchestrated regulation in latency of TGF-β enables the imme-
diate and highly localized response to type-speciﬁc tissue injury
without de novo synthesis. In this scenario, the ECM is potentially
an important regulator of latent TGF-β complexes. One of the
compelling themes in recent years is to clarify the crucial roles
of integrin β6, thrombospondin-1 (TSP-1), LTBPs, ﬁbrillin-1, and
ﬁbronectin in regulating local TGF-β activity and locally anchored
TGF-β availability in pathological process (Hynes, 2009).
MECHANISMS OF TGF-β ACTIVATION
Local activation of latent (inactive) TGF-β complexes is a critical
event in regulating TGF-β function in vivo. In response to tissue
damage, TGF-β is released from LAP or latent TGF-β complex
Table 1 | AlteredTGF-β activity in knockout or mutant mice.
Gene target Treatment TGF-β activity Reference
Integrin β6 Bleomycin-induced lung ﬁbrosis Decrease Munger et al. (1999)
BDL-induced liver ﬁbrosis Decrease Wang et al. (2007)
TSP-1 Decrease Crawford et al. (1998)
PH-induced liver regeneration Decrease Hayashi et al. (2011)
Bleomycin-induced lung ﬁbrosis Not affected Ezzie et al. (2011)
Thrombopoietin-induced myeloﬁbrosis Not affected Evrard et al. (2011)
Fibronectin CCl4-induced liver injury Increase Moriya et al. (2011)
LTBP1 Decrease Todorovic et al. (2007)
LTBP3 Decrease Dabovic et al. (2002)
LTBP4 Decreases Sterner-Kock et al. (2002)
BMP-1 andTll1 Decrease Ge and Greenspan (2006)
Fibrillin-1 Increase Neptune et al. (2003)
MAGP-1 Decrease Weinbaum et al. (2008)
Fibulin-4 Increase Hanada et al. (2007)
Emilin-1 Increase Zacchigna et al. (2006)
TGF-β1–LAP (C33 S) Decrease Yoshinaga et al. (2008)
TGF-β, transforming growth factor-β; BDL, bile duct ligation;TSP-1, thrombospondin-1; PH, partial hepatectomy; LTBP, large latentTGF-β-binding protein; BMP-1, bone
morphogenetic protein-1; TII1, tolloid-like 1; CCl4, Carbon tetrachloride; MAGP-1, microﬁbril-associated glycoprotein-1; LAP, latency-associated peptide; C33S, 33
cysteine mutated to serine.
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FIGURE 2 | Proposed model ofTGF-β latent complex and activeTGF-β
signaling.The LTBP is covalently cross-linked to ECMs such as ﬁbronectin
and ﬁbrillin via its N-terminal and C-terminal region, respectively. The small
latent TGF-β complex is bound covalently to the third cysteine-rich domain
of LTBP. In response to tissue injury, release of active TGF-β from latent
complex and/or conformational change such as exposure of theTGF-β
receptor binding site is induced. Binding of active TGF-β with theTGF-β
receptor type II leads to the phosphorylation and recruitment of TGF-β
receptor type I into a heteromeric receptor complexes.The serine/threonine
kinase activity of the activated complex phosphorylates Smad2 and Smad3
that both bind to Smad4 and translocate into the nucleus to enhance gene
transcription by cooperating with DNA transcription factors.
undergoes conformational changes, and therefore, active TGF-
β is exposed to the TGF-β receptor binding site (Annes et al.,
2003). Binding of active TGF-β to the TGF-β receptor type II
leads to the phosphorylation and recruitment of TGF-β receptor
type I into a heteromeric receptor complex. The serine/threonine
kinase activity of the activated complexphosphorylates Smad2 and
Smad3 that both bind to Smad4 and translocate into the nucleus
to enhance gene transcription by cooperating with DNA tran-
scription factors (Feng and Derynck, 2005; Massague et al., 2005;
Matsuzaki, 2012; Figure 2). The activation mechanism to generate
active TGF-β from latent complexes has been extensively stud-
ied, and several modulators of TGF-β activity in vivo have been
proposed.
INTEGRIN-MEDIATED TGF-β ACTIVATION
Recent studies show that integrins-related genetic models can
down-regulate TGF-β activation in vivo (Munger et al., 1999; Yang
et al., 2007). Integrins are heterodimeric cell adhesion molecules
and transmembrane receptors that link the ECM to the cytoskele-
ton, and have an important role in cell adhesion, cell proliferation,
differentiation, and cell migration (Hynes, 1992, 2002; van der
Flier and Sonnenberg, 2001). Integrins are composed of α- and β-
subunits (18 α- and 8 β-subunits), both of which are glycoproteins
consisting of large extracellular domains and, inmost cases, a short
cytoplasmic domain (van der Flier and Sonnenberg, 2001). Both
TGF-β1 and LAP have an RGD sequence, a binding motif in lig-
ands for αv integrins. Among the αv integrins, the integrins αvβ1,
αvβ3, αvβ5, αvβ6, αvβ8, α5β1, α8β1, and αIIbβ3 are RGD bind-
ing integrins. Mice with the integrin-binding RGD motif mutated
to RGD recapitulate all major phenotypes of TGF-β1-null mice,
includingmulti-organ inﬂammation and defects in vasculogenesis
(Yang et al., 2007). Two of these integrins (αvβ6 and αvβ8) bind
and efﬁciently activate latent TGF-β1 and -β3 (Munger et al., 1999;
Annes et al., 2002; Mu et al., 2002; Araya et al., 2006).
The integrin identiﬁed as a TGF-β activator in vivo is αvβ6,
which can directly activate latent TGF-β1 independently from
any proteolytic activity (Munger et al., 1999). The αvβ6 integrin-
mediated activation of latent TGF-β depends on a direct inter-
action between integrin αvβ6 and the RGD amino acid sequence
present in LAP β1 and LAP β3. However, binding alone is not suf-
ﬁcient to activate the latent complex (Munger et al., 1999). The
interaction of the β6 cytoplasmic domain with the actin cytoskele-
ton is mandatory for this activation (Munger et al., 1999). LTBP-1
is identiﬁed as being a major regulatory factor in αvβ6-integrin-
mediated TGF-β activation. This activation requires a covalent
interaction between LAP and the third cysteine-rich domain in
LTBP mediated by a hinge domain of LTBP-1 (Annes et al., 2004).
Since the hinge domain of LTBP-1 is not conserved among other
LTBP isoforms, αvβ6-mediated TGF-β activation via LTBP-1 is
isoform speciﬁc (Annes et al., 2004; Wipff and Hinz, 2008). In
response to tissue injury or tissue damage, integrin αvβ6 induces
a conformational change of latent TGF-β via the interactions
between integrin αvβ6 and actin cytoskeleton (Munger et al., 1999;
Wipff and Hinz, 2008; Shi et al., 2011). Such a conformational
change makes it possible to cause mature TGF-β to interact with
the TGF-β type II receptor (Munger et al., 1999; Wipff and Hinz,
2008; Shi et al., 2011). There is no release of LAP or active TGF-β1
once latent TGF-β associates with integrin αvβ6. Although a proﬁ-
brogenic drug bleomycin induces lung ﬁbrosis in wild-type mice
by up-regulation of integrin β6 expression in alveolar epithelial
cells and activation of TGF-β, even high dose of bleomycin admin-
istration cannot cause ﬁbrosis in integrin β6-null mice (Munger
et al., 1999).
TSP-1-MEDAITED TGF-β ACTIVATION
The matricellular protein TSP-1 was ﬁrst shown as a component
of the α-granule in platelets and can act as a major activator
of latent TGF-β1 (Mosher, 1990; Crawford et al., 1998). TSP-1
is prominently expressed in response to tissue damage or stress
and plays a role as a transient component of ECM during tissue
repair (Mosher, 1990; Adams, 2001; Kyriakides and Maclauchlan,
2009). TSP-1 binds to matrix components, proteases, cytokines,
and growth factors and activates intracellular signals via its mul-
tiple domains, and thereby modulates cell adhesion, inhibition of
angiogenesis, and reconstruction of the ECM (Bornstein, 2009).
Furthermore, TSP-1 can activate latent TGF-β1 in vitro (Schultz-
Cherry and Murphy-Ullrich, 1993; Schultz-Cherry et al., 1994a)
and in vivo (Crawford et al., 1998). Indeed, TSP-1 activates recom-
binant small and large latent TGF-βs even in a cell-free system,
and this activation is inhibited by a speciﬁc antibody for the
amino-terminus of the LAP but not for the COOH terminus of
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the LAP and the LTBP (Schultz-Cherry et al., 1994a). Thus, TSP-1
binds small latent TGF-β and large latent TGF-β, and this bind-
ing interaction is sufﬁcient to generate biologically active TGF-β.
The two sequences (GGWSHW and KRFK) located in the type
I repeat of TSP-1 comprise the region responsible for binding
and activating latent TGF-β, respectively (Goundis and Reid, 1988;
Schultz-Cherry et al., 1994b). In LAP, a sequence LSKL near the
amino-terminus plays a pivotal role in the interaction and TSP-
1-mediated activation of latent TGF-β, because LSKL peptides
competitively inhibit TSP-1- or a KRFK-peptide-mediated latent
TGF-β activation (Ribeiro et al., 1999). Furthermore, mutations
of the LSKL sequence in LAP reduce the binding of LAP to the
mature TGF-β and induce the impaired ability of LAP to confer
latency to mature TGF-β (Young and Murphy-Ullrich, 2004). Such
a direct interaction between TSP-1 and LAP is supposed to induce
a conformational change of LAP in relation to mature TGF-β and
thereby presumably unmask the TGF-β receptor binding site that
can bind to its receptor (Murphy-Ullrich and Poczatek, 2000). To
further understand TSP-1-mediated TGF-β activation, the nature
of structural restraints imposed on LAP in the presence of bound
TSP-1 would be useful. TSP-1-null mice have an inﬂammatory
phenotype similar to that of TGF-β1-null mice in several organs,
including pancreas and lung, whereas the inﬂammatory changes
observed in TSP-1-null mice are not as severe as those in TGF-β1-
null mice (Crawford et al., 1998). Treatment of TSP-1-null mice
with the TSP-1 derived peptide KRFK, which activates TGF-β1,
rescues the abnormal phenotypes in pancreas and lung (Craw-
ford et al., 1998). In contrast, the treatment of wild-type mice
with the peptide LSKL, which blocks TGF-β activation, results in
the abnormalities in pancreas and lung, and these phenotypes are
very similar to those of TSP-1-null mice and TGF-β1-null mice
(Crawford et al., 1998).
PROTEASE-MEDIATED TGF-β ACTIVATION
A number of proteases, including plasmin, matrix metallopro-
teinase (MMP)-2/9, and a disintegrin and metalloproteinase with
TSP motifs 1 (ADAMTS1), have been identiﬁed as latent TGF-
β activators in vitro (Lyons et al., 1988; Sato and Rifkin, 1989;
Yu and Stamenkovic, 2000; Bourd-Boittin et al., 2011). Plasmin
and MMP-2/9 belong to the serine protease and metallopro-
teinase families, respectively. The proteinase-sensitive hinge region
in LTBP is suggested to be a potential target for the release of
a still-latent remnant of the large latent complex (Taipale et al.,
1994). Using a co-culture system of endothelial cells and peri-
cytes or smooth muscle cells, plasmin has been identiﬁed as one
of the latent TGF-β activators in vitro: the active TGF-β forma-
tion is blocked by plasmin inhibitors (Sato and Rifkin, 1989)
or prolonged by neutralizing antibody to plasminogen activa-
tor inhibitor-1 (Sato et al., 1990). The treatments of ﬁbroblast-
or Chinese hamster ovary cell-conditional medium with plas-
min can generate the active form of TGF-β (Lyons et al., 1988,
1990). Thus, the proteinase-mediated TGF-β activation system
appears to be important in activation of latent TGF-β in sev-
eral models in vitro. However, there is still no deﬁnite evidence of
proteinase-dependent TGF-β activation in vivo. Indeed, plasmino-
gen (plasmin pro-enzyme)-null mice show normal embryonic
development, survive to adulthood, are fertile, and display none of
the pathological features shown in TGF-β-null mice (Bugge et al.,
1995).
TGF-β ACTIVATION MECHANISM AND AVAILABILITY OF
LATENT TGF-β COMPLEX IN LIVER DISEASES
Transforming growth factor-β signal induces the transition of
quiescent hepatic stellate cells (HSCs) into contractile ﬁbrogenic
myoﬁbroblasts, which is the key event in the pathobiology of
liver ﬁbrosis (Bissell et al., 2001; Dooley et al., 2003; Gressner
and Weiskirchen, 2006). Myoﬁbroblasts play a central role in the
production of ECM components such as ﬁbronectin, collagen
type I and III. Continuous and/or upregulated TGF-β-signaling,
such as in chronic liver injury, induces sustained activation of
myoﬁbroblasts and results in liver ﬁbrosis (Bissell et al., 2001;
Tahashi et al., 2002; Gressner and Weiskirchen, 2006). Active
TGF-β-signaling acts on hepatocytes as an anti-proliferative factor
in culture, and administration of TGF-β inhibits the hepatocyte
proliferation during liver regeneration after partial hepatectomy
(Russell et al., 1988). Genetic ablation of TGF-β-signals using TGF
type II receptor-knockout mice actually accelerates hepatocyte
proliferation after partial hepatectomy (Oe et al., 2004). Thus,
locally activated TGF-β-signaling is involved in the repair follow-
ing liver injury, and the therapeutic strategies targeting local TGF-β
activation in ﬁbrogenesis are now under intense investigation
(Table 2).
β6 INTEGRIN-MEDIATED LOCAL TGF-β BIOAVAILABILITY AND LIVER
DISEASES
Expression of αvβ6-integrin is virtually absent except in cholangio-
cytes in normal liver, but its expression in cholangiocytes is highly
upregulated in thioacetamide- and bile duct ligation-induced
ﬁbrotic liver (Wang et al., 2007; Popov et al., 2008). Deﬁciency in
integrin β6 attenuates liver ﬁbrosis after bile duct ligation, which is
accompanied by a decrease in active TGF-β-signaling (Wang et al.,
2007). In human ﬁbrogenic liver diseases (e.g., primary biliary cir-
rhosis, primary sclerosing cholangitis, alcoholic liver disease, and
hepatitis B or C),αvβ6-integrin mRNA levels are upregulated com-
pared to levels in healthy livers (Popov et al., 2008). Furthermore,
αvβ6-integrin mRNA levels correlate with the progression of ﬁbro-
sis in patients with chronic hepatitis C (Popov et al., 2008). These
ﬁndings suggest that αvβ6-integrin may be involved not only in
classic biliary type ﬁbrosis but also in a variety of liver ﬁbrogenic
diseases with different etiologies (Popov et al., 2008).
TSP-1-MEDAITED LOCAL TGF-β BIOAVAILABILITY AND LIVER DISEASES
The roles of TSP-1/TGF-β1 interdependence during liver regen-
eration remain to be elucidated. We have investigated whether
TSP-1 is a suitable molecular target for accelerating liver regen-
eration after partial hepatectomy using a TSP-1-deﬁcient mouse
model. We have found that TSP-1 is prominently induced in
endothelial cells of wild-type livers in response to partial hepa-
tectomy, and thereafter TGF-β signal is activated. TSP-1 deﬁciency
results in signiﬁcantly reduced TGF-β/Smad signaling and accel-
erated hepatocyte proliferation via downregulation of p21 protein
expression. TSP-1 expression in endothelial cells such as human
umbilical vein endothelial cells (HUVECs) is induced by reac-
tive oxygen species (ROS) in culture. Treatment of those condi-
tioned media from HUVECs with primary hepatocytes actually
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Table 2 |Therapeutic target forTGF-β activation mechanism in vivo.
Target model Reagent Effect TGF-β activity Reference
INTEGRIN β6
BDL-induced liver ﬁbrosis Antagonist Decrease Decrease Patsenker et al. (2008)
BDL-induced liver ﬁbrosis Antibody Decrease NA Wang et al. (2007)
Bleomycin-induced lung ﬁbrosis Antibody Decrease Decrease Horan et al. (2008)
Radiation-induced lung ﬁbrosis Antibody Decrease NA Puthawala et al. (2008)
TSP-1
Bleomycin-induced lung ﬁbrosis Peptide Decrease Decrease Chen et al. (2009a), Chen et al. (2009b)
UUO-induced renal ﬁbrosis Peptide Decrease Decrease Xie et al. (2010)
DMN-induced liver ﬁbrosis Peptide Decrease Decrease Kondou et al. (2003)
PLASMIN
PC-induced liver ﬁbrosis Inhibitor Decrease Decrease Okuno et al. (2001)
ADAMTS1
CCl4-induced liver ﬁbrosis Peptide Decrease NA Bourd-Boittin et al. (2011)
TGF-β, transforming growth factor-β; PC, porcine serum; BDL, bile duct ligation; NA, not available; TSP-1, thrombospondin-1; UUO, Unilateral ureteral obstruction;
DMN, dimethylnitrosamine; CCl4, carbon tetrachloride.
induces phosphorylation of Smad2. Furthermore, pretreatment
of primary hepatocytes with the TSP-1-inhibitory peptide LSKL
signiﬁcantly suppresses conditioned media-induced phosphory-
lation of Smad2, whereas pretreatment of primary hepatocytes
with the control peptide SLLK shows no effects. Thus, these
ﬁndings indicate that TSP-1 plays a negative role in liver regen-
eration through local TGF-β1 activation (Hayashi et al., 2011).
Furthermore, treatment with the TSP-1 inhibitory peptide LSKL
reduces local TGF-β activity and suppresses the progressionof liver
ﬁbrosis in a dimethylnitrosamine (DMN)-treated rat liver ﬁbrosis
model, suggesting that TSP-1-mediated local TGF-β activation is
associated with liver ﬁbrogenesis (Kondou et al., 2003).
FIBRONECTIN-MEDIATED LOCAL TGF-β BIOAVAILABILITY AND LIVER
DISEASES
Fibronectin is a major ECM component and exists in soluble
(plasma ﬁbronectin) and insoluble form (cellular ﬁbronectin) as a
part of the ECM (Hynes, 1986;Mosher, 1989). Fibronectin partici-
pates in the incorporation of LTBP-1 into the ECM in vitro (Dallas
et al., 2005). Fibronectin-null cells show poor activity vis-à-vis
LTBP-1 incorporation into the ECM and exhibit deﬁcient activa-
tion of latent TGF-β1 even after transfection by the integrin αvβ6,
suggesting that ﬁbronectin is necessary to the ECM scaffold for
LTBP-1 deposition (Fontana et al., 2005). To investigate the inter-
dependence of ﬁbronectin and TGF-β on the ﬁbrogenic response
to adult tissue damage, we recently established a null condition for
both ﬁbronectin isoforms (plasma and cellular types) from adult
mouse liver. Since it has been proposed that collagen organization
and assembly depend on the ﬁbronectin matrix in culture (Sottile
and Hocking, 2002;Velling et al., 2002; Sottile et al., 2007),we have
explored whether ﬁbronectin would be a suitable molecular target
for preventing the extensive collagen deposits and scar formation
that could lead to liver ﬁbrosis. We have demonstrated that the
lack of ﬁbronectin does not actually interfere with reconstruction
of collagen ﬁbril organization in response to carbon tetrachloride-
induced liver injury. Fibronectin deﬁciency results in elevated local
TGF-β bioavailability post injury, and it is mediated largely by β6
integrin. Furthermore, we have identiﬁed TGF-β-signaling and
type V collagen as essential elements for collagen ﬁbrillogenesis
in adult tissue remodeling (Moriya et al., 2011). Our ﬁndings
imply that ﬁbronectin regulates the balance of active and inac-
tive (latent) TGF-β, which in turn modulates ECM production
and remodeling and consequently maintains adult liver home-
ostasis. Indeed, mouse models of TGF-β1 overexpression show
dominant phenotypes such as advanced liver ﬁbrosis (Sanderson
et al., 1995; Ueberham et al., 2003). These observations sup-
port the hypothesis that LTBP and its binding molecules such as
ﬁbronectin determine the spatial localization of LTBP in tissues,
thereby regulating the extent of local TGF-β bioavailability. Since
locally activated TGF-β induces the production of type V collagen
in response to liver damage, it remains to be elucidated whether
type V collagen-nucleated collagen ﬁbrillogenesis contributes to
adult chronic ﬁbrotic diseases.
PROTEINASE-MEDIATED LOCAL TGF-β BIOAVAILABILITY AND LIVER
DISEASES
A very recent study using a proteinase-related gene sample iden-
tiﬁed ADAMTS1 as an upregulated ﬁbrosis-related protease in
human liver ﬁbrosis (Bourd-Boittin et al., 2011). ADAMTSs
are characterized by an ancillary domain containing one or
more TSP type 1 repeats (Apte, 2009). ADAMTSs are secreted
as cell surface proteins and associate with ECM components.
ADAMTS1 is synthesized as a 110-kDa latent form and processed
by HSCs as 87-kDa mature forms in ﬁbrotic tissues (Bourd-
Boittin et al., 2011). A major feature of ADAMTS1 is the
presence of three TSP type 1 motifs and a KTFR motif.
There is a direct interaction between ADAMTS1 and LAP, and
ADAMTS1 induces local TGF-β activation through the interac-
tion between ADAMTS1-derived KTFR and LAP-derived LSKL
(Bourd-Boittin et al., 2011). The expression of ADAMTS1 is
induced in mouse chronic liver ﬁbrosis model induced by car-
bon tetrachloride, and administrations of KTFR peptide reduce
liver ﬁbrosis (Bourd-Boittin et al., 2011). Another study demon-
strated that plasmin inhibitor, camostat mesilate, can sup-
press TGF-β activation in HSCs in vitro, and oral adminis-
trations of camostat mesilate attenuates the development of
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porcine-serum-induced liver ﬁbrosis in rats (Okuno et al.,
2001).
TRANSGLUTAMINASE-MEDIATED LOCAL TGF-β BIOAVAILABILITY AND
LIVER DISEASES
Covalent cross-linking between proteins is catalyzed by transg-
lutaminases. This is an important process for tissue remodeling,
as it generates extra rigidity and a resistance against proteolytic
degradation. The family of transglutaminases (EC2.3.2.13) con-
sists of eight family members (transglutaminase 1–7 and plasma
coagulation factor XIII (Beninati and Piacentini, 2004). The
covalent association between LTBP-1 and the ECM depends on
transglutaminase-mediated cross-linking, because little LTBP-1
is recovered from matrix digests prepared from cultures treated
with transglutaminase inhibitors (Nunes et al., 1997). Further-
more, transglutaminase inhibitors prevent TGF-β1 activation in a
co-culture of bovine aortic endothelial cells and bovine smooth
muscle cells (Kojima et al., 1993). Thus, transglutaminase is
important for the LTBP anchoring to ECM, and transglutaminase
inhibitors affect TGF-β1 activity in vitro. Transglutaminase 2 is
involved in several human diseases, in wound healing and ﬁbrosis,
and represents promising pharmacological targets (Verderio et al.,
2004; Caccamo et al., 2010). Indeed, transglutaminase 2 deﬁciency
reduces levels of active TGF-β1 and attenuates the interstitial renal
ﬁbrosis induced by unilateral ureteral obstruction inmice (Shweke
et al., 2008).
Elevated transglutaminase 2 expression and activity are
observed in human ﬁbrotic (Grenard et al., 2001) and mouse
CCl4-treated livers (Nardacci et al., 2003; Popov et al., 2011).
Transglutaminase 2-null mice fail to clear hepatic necrotic tissues
and to rearrange the hepatic lobular architecture with a progres-
sive accumulation of ECM components and inﬂammatory cells
in CCl4-induced chronic liver injury, indicating that transglu-
taminase 2 plays a protective role in tissue stability and repair
after liver injury (Nardacci et al., 2003; Popov et al., 2011). Very
recently, Popov et al. (2011) assessed whether transglutaminase 2
was implicated in irreversible collagen stabilization in liver ﬁbrosis.
Transglutaminase 2 activity is upregulated during hepatic ﬁbroge-
nesis or stabilization of collagen matrix. However, unexpectedly,
transglutaminase 2 deﬁciency does not promote regression of liver
ﬁbrosis (Popov et al., 2011). Thus, there exists transglutaminase 2-
independent irreversible collagen cross-linking in the progression
of liver ﬁbrosis (Popov et al., 2011).
Although most antiﬁbrotic strategies are directed against HSC
/myoﬁbroblast proliferation and proﬁbrogenic activation, few
studies have targeted ECM stabilization. Considering the evidence
that the instability of ECM bounded latent TGF-β complex results
in altered TGF-β availability (Maeda et al., 2011), the targeting
for ECM-mediated TGF-β bioavailability would be an alternative
therapeutic approach for preventing progression of liver ﬁbrosis.
PERSPECTIVE
Transforming growth factor-β is synthesized as a small latent com-
plex (mature TGF-β and LAP) and thereafter covalently interacts
with LTBPs as the large latent complex. The large latent complex
is associated with ECM components, ﬁbrillin, and ﬁbronectin.
Such a well and tightly orchestrated regulation in latency of
TGF-β enables an immediate and highly localized response to
type-speciﬁc tissue injury without de novo synthesis.
Both β6 integrin- and TSP-1-mediated local TGF-β activation
are involved in the pathogenesis of liver diseases. Interestingly, in
other organs such as lung, the lack of TSP-1 does not affect TGF-
β bioavailability and does not protect from bleomycin-induced
pulmonary ﬁbrosis (Ezzie et al., 2011). In the thrombopoietin-
induced bone marrow myeloﬁbrosis model, TSP-1 deﬁciency
does not attenuate local TGF-β bioavailability and myeloﬁbrosis
(Evrard et al., 2011). Thus, mechanisms of local TGF-β activation
and their biological signiﬁcance in the pathological process are
likely to be tissue speciﬁc.
Based on the TGF-β signaling pathway, four major strategies
allowing the modulation of TGF-β availability have emerged. The
ﬁrst strategy is to block the production of TGF-β using anti-sense
oligonucleotide mRNA; a second is to use monoclonal antibodies
to block speciﬁc TGF-β isoforms; a third is to use the intracellu-
lar signal inhibitors that block the TGF-β receptor activation and
downstream signaling; and a fourth, which constitutes the main
focus of this review, is to block the local activation of latent TGF-
β. Since TGF-β has so many important physiological functions, as
evidenced by TGF-β-null mice, a long-term global inhibition of
TGF-β activity might potentially lead to undesirable side effects,
such as aberrant immune activation, impaired wound healing,
and malignant cell transformation (Kulkarni et al., 1993; Mallat
et al., 2001; Bhowmick et al., 2004). Careful targeting of the TGF-β
pathway to minimize systemic effects is clearly a highly desir-
able goal. Anti-TGF-β strategies to selectively block latent TGF-β
activation at local sites where excess TGF-β activation occurs are
attractive and logical. The beneﬁts of therapeutic strategies target-
ing local TGF-β activation are under intense investigation. Future
studies will yield valuable data about these strategies for liver
diseases.
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